Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 6/20 | 0.54 |
| ▸ | BCDIN3D | Q7Z5W3 | 6/20 | 0.48 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828357 | 0.79 | PDE2A (0.66) | PDE2AHTR2CBCDIN3DSHMT2KMT2A | |
| SCHEMBL29487109 | 0.79 | PDE2A (0.66) | PDE2AHTR2CBCDIN3DSHMT2KMT2A | |
| SCHEMBL13828311 | 0.79 | PDE2A (1.00) | PDE2AHTR2CBCDIN3DKMT2AKDM4E | |
| SCHEMBL17450152 | 0.75 | HTT (0.64) | PDE2AHTR2CBCDIN3D | |
| SCHEMBL130798 | 0.75 | PI4KA (0.53) | PDE2AHTR2CBCDIN3DKMT2AKDM4E | |
| SCHEMBL13828410 | 0.72 | HTR2C (0.46) | PDE2AHTR2CBCDIN3DKMT2AMEN1 | |
| SCHEMBL29854071 | 0.71 | KDM4E (0.68) | PDE2AKMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL13828337 | 0.68 | HRH4 (0.66) | HTR2CBCDIN3DKMT2AMEN1MAPT | |
| SCHEMBL17792782 | 0.68 | SHMT2 (0.69) | PDE2ABCDIN3DSHMT2KMT2AMEN1 | |
| SCHEMBL14898534 | 0.67 | ALDH1A1 (0.49) | PDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDE2A 803/4885HTR2C 3685/4885BCDIN3D 2819/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDE2A 803/4885HTR2C 3685/4885BCDIN3D 2819/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDE2A 803/4885HTR2C 3685/4885BCDIN3D 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.